About BioViva’s first gene therapy experiment against ageing

The news about BioViva’s first successful intervention on human ageing is not exactly news any more. When your post backlog is as long as mine is, you inevitably end up with some stale news that are still worth dropping a line.

Some months ago, the company BioViva made its first attempt to intervene on an aspect of human ageing through gene therapy. Specifically, the very company’s CEO, Elizabeth Parrish, ‘[…] received two of her own company’s experimental gene therapies: one to protect against loss of muscle mass with age, another to battle stem cell depletion responsible for diverse age-related diseases and infirmities.’

Long story short, as a consequence of the treatment, Parrish’s leukocytes’ telomeres seem to be longer than they usually are at her age. Data seems to indicate they’ve been ‘rejuvenated’ by 20 years.

However, one must understand this is an experiment with a sample size of one, and that BioViva’s CEO will have to be monitored for years to come to make sure the data is correct and there are no nasty side-effects. FightAging! has also voiced a slight skepticism, not so much in the reliability of the data, but rather on the actual correlation between age and telomere length.

I guess we can only wait and see.

BioViva treats first patient with gene therapy to reverse ageing

Some time ago I posted about BioViva, a new biotech company working on a cure for ageing led by Liz Parrish. In the video of the post, Liz appeared to be quite enthusiastic about what her company is doing and said that the company would hopefully have some results to show as soon as some point in 2016. Today, I stumbled upon an article on PrWeb, according to which “BioViva USA, Inc. has become the first company to treat a person with gene therapy to reverse biological aging, using a combination of two therapies developed and applied outside the United States of America. […] the subject is doing well and has resumed regular activities. Preliminary results will be evaluated at 5 and 8 months with full outcome expected at 12 months. The patient will then be monitored every year for 8 years […]. I suppose this is what Liz was talking about in the video, even though I haven’t find trace of the news on BioViva’s website (well, their site could use some work, I must say).

At any rate, I’m looking forward to hear again about this in a couple of months.

Ageing, meet Liz Parrish

Elizabeth Parrish, CEO of BioViva Sciences, gives an interesting talk on how her company plans to put an end to ageing: engineered genomics. I seem to understand that there were other talks at the same event, I think at least one held by Bill Andrews and possibly Aubrey de Grey; I will post them if I find them.